Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

Isadora Lopes Alves, Lyduine E. Collij, Daniele Altomare, Giovanni B. Frisoni, Laure Saint-Aubert, Pierre Payoux, Miia Kivipelto, Frank Jessen, Alexander Drzezga, Annebet Leeuwis, Alle Meije Wink, Pieter Jelle Visser, Bart N. M. van Berckel, Philip Scheltens, Katherine R. Gray, Robin Wolz, Andrew Stephens, Rossella Gismondi, Christopher Buckely, Juan Domingo GispertMark Schmidt, Lisa Ford, Craig Ritchie, Gill Farrar, Frederik Barkhof, Jose Luis Molinuevo

Research output: Contribution to journalArticleAcademicpeer-review


INTRODUCTION: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD-related progression as well as address methodological challenges in amyloid PET.

METHODS: AMYPAD PNHS is an open-label, prospective, multi-center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow-up PET 12 at least 12 months later.

RESULTS: Primary include several amyloid PET measurements (Centiloid, SUVr, BPND , R1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline.

EXPECTED IMPACT: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.

Original languageEnglish
Pages (from-to)750-758
Number of pages9
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Issue number5
Publication statusPublished - May 2020

Cite this